Differences in adverse event profiles between everolimus and temsirolimus and the risk factors for non-infectious pneumonitis in advanced renal cell carcinoma

International Journal of Clinical Oncology ◽

10.1007/s10147-014-0764-5 ◽

2014 ◽

Vol 20 (4) ◽

pp. 790-795 ◽

Author(s):

Masahiro Nozawa ◽

Takayuki Ohzeki ◽

Satoshi Tamada ◽

Fumiya Hongo ◽

Satoshi Anai ◽

...

Keyword(s):

Risk Factors ◽

Renal Cell Carcinoma ◽

Adverse Event ◽

Cell Carcinoma ◽

Advanced Renal Cell Carcinoma

Download Full-text

PCN111 COMPARISON OF ADVERSE EVENT COSTS OF NIVOLUMAB+IPILIMUMAB VERSUS SUNITINIB FOR PREVIOUSLY UNTREATED INTERMEDIATE-/POOR-RISK ADVANCED RENAL CELL CARCINOMA IN SWITZERLAND

Value in Health ◽

10.1016/j.jval.2019.09.308 ◽

2019 ◽

Vol 22 ◽

pp. S457

Author(s):

C. Oniangue-Ndza ◽

K.M. Gooden ◽

J. May ◽

B. Malcolm ◽

E.X. Du ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Adverse Event ◽

Cell Carcinoma ◽

Advanced Renal Cell Carcinoma ◽

Download Full-text

7160 Evaluation of adverse event -related hospitalizations in patients with advanced renal cell carcinoma on treatment with temsirolimus or interferon-alfa: results from a phase 3 randomized trial

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(09)71493-4 ◽

2009 ◽

Vol 7 (2) ◽

pp. 441

Author(s):

S. Rajagopalan ◽

E. Pullenayegum ◽

E. Alemao ◽

A. Strahs ◽

J. Purvis

Keyword(s):

Renal Cell Carcinoma ◽

Adverse Event ◽

Randomized Trial ◽

Cell Carcinoma ◽

Interferon Alfa ◽

Advanced Renal Cell Carcinoma ◽

Download Full-text

PCN115 COMPARISON OF ADVERSE EVENT COSTS OF NIVOLUMAB+IPILIMUMAB VERSUS SUNITINIB FOR PREVIOUSLY UNTREATED INTERMEDIATE-/POOR-RISK ADVANCED RENAL CELL CARCINOMA IN SPAIN

Value in Health ◽

10.1016/j.jval.2019.09.312 ◽

2019 ◽

Vol 22 ◽

pp. S458

Author(s):

C. Polanco Sánchez ◽

K.M. Gooden ◽

J. May ◽

B. Malcolm ◽

E.X. Du ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Adverse Event ◽

Cell Carcinoma ◽

Advanced Renal Cell Carcinoma ◽

Download Full-text

Risk factors for sorafenib-induced high-grade skin rash in Japanese patients with advanced renal cell carcinoma

Anti-Cancer Drugs ◽

10.1097/cad.0b013e32835c401c ◽

2013 ◽

Vol 24 (3) ◽

pp. 310-314 ◽

Author(s):

Norihiko Tsuchiya ◽

Shintaro Narita ◽

Takamitsu Inoue ◽

Naoko Hasunuma ◽

Kazuyuki Numakura ◽

...

Keyword(s):

Risk Factors ◽

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Skin Rash ◽

Japanese Patients ◽

Advanced Renal Cell Carcinoma ◽

Download Full-text

Experiences and practical conclusions concerning temsirolimus use and adverse event management in advanced renal cell carcinoma within a compassionate use program in Germany

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-008-0835-2 ◽

2008 ◽

Vol 63 (6) ◽

pp. 1097-1102 ◽

Author(s):

Holger Gerullis ◽

Lothar Bergmann ◽

Luise Maute ◽

Christoph Eimer ◽

Thomas Otto

Keyword(s):

Renal Cell Carcinoma ◽

Adverse Event ◽

Cell Carcinoma ◽

Advanced Renal Cell Carcinoma ◽

Event Management ◽

Compassionate Use ◽

Adverse Event Management

Download Full-text

Treatment‐Associated Adverse Event Management in the Advanced Renal Cell Carcinoma Patient Treated with Targeted Therapies

The Oncologist ◽

10.1634/theoncologist.2011-s2-32 ◽

2011 ◽

Vol 16 (S2) ◽

pp. 32-44 ◽

Author(s):

Alain Ravaud

Keyword(s):

Renal Cell Carcinoma ◽

Adverse Event ◽

Cell Carcinoma ◽

Targeted Therapies ◽

Renal Cell Carcinoma Patient ◽

Advanced Renal Cell Carcinoma ◽

Event Management ◽

Carcinoma Patient ◽

Adverse Event Management

Download Full-text

UP-2.097: Experiences and Practical Conclusions Concerning Temsirolimus Use and Adverse Event Management in Advanced Renal Cell Carcinoma Within a Compassionate Use Program in Germany

Urology ◽

10.1016/j.urology.2009.07.316 ◽

2009 ◽

Vol 74 (4) ◽

pp. S261

Author(s):

H. Gerullis ◽

L. Bergmann ◽

L. Maute ◽

J. Bagner ◽

C. Eimer ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Adverse Event ◽

Cell Carcinoma ◽

Advanced Renal Cell Carcinoma ◽

Event Management ◽

Compassionate Use ◽

Adverse Event Management

Download Full-text

Risk Factors and Patterns of Locoregional Recurrence After Radical Nephrectomy for Locally Advanced Renal Cell Carcinoma

Cancer Research and Treatment ◽

10.4143/crt.2020.1373 ◽

2021 ◽

Author(s):

Gyu Sang Yoo ◽

Won Park ◽

Hongryull Pyo ◽

Byong Chang Jeong ◽

Hwang Gyun Jeon ◽

...

Keyword(s):

Risk Factors ◽

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Radical Nephrectomy ◽

Locoregional Recurrence ◽

Locally Advanced ◽

Advanced Renal Cell Carcinoma

Download Full-text

PCN143 COMPARISON OF ADVERSE EVENT COSTS OF NIVOLUMAB+IPILIMUMAB VERSUS SUNITINIB FOR PREVIOUSLY UNTREATED INTERMEDIATE-/POOR-RISK ADVANCED RENAL CELL CARCINOMA IN PORTUGAL

Value in Health ◽

10.1016/j.jval.2019.09.339 ◽

2019 ◽

Vol 22 ◽

pp. S463

Author(s):

D. Alves ◽

C. Polanco Sánchez ◽

K.M. Gooden ◽

J. May ◽

B. Malcolm ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Adverse Event ◽

Cell Carcinoma ◽

Advanced Renal Cell Carcinoma ◽

Download Full-text

1104 Frequency and risk factors of sorafenib-induced high-grade skin rash in Japanese patients with advanced renal cell carcinoma

European Urology Supplements ◽

10.1016/s1569-9056(13)61579-1 ◽

2013 ◽

Vol 12 (1) ◽

pp. e1104-e1105

Author(s):

N. Tsuchiya ◽

S. Narita ◽

T. Inoue ◽

N. Hasunuma ◽

K. Numakura ◽

...

Keyword(s):

Risk Factors ◽

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Skin Rash ◽

Japanese Patients ◽

Advanced Renal Cell Carcinoma ◽

Download Full-text